Semaglutide for Cognition: What the Evidence Shows
What human and animal studies show about Semaglutide for cognition, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Human RCT
- Human studies
- 3
- with an outcome for cognition, in our evidence file (PubMed search, 2 Oct 2026)
- Animal studies
- None found
- with an outcome for cognition, in our evidence file (PubMed search, 2 Oct 2026)
- Studies we summarised
- 3
- with an outcome for cognition
Evidence for cognition
Each row is an outcome related to cognition from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Clinical Dementia Rating-Sum of Boxes | Oral semaglutide did not slow clinical progression in early Alzheimer disease; both trials were discontinued for negative outcome. | Human RCTn = 3808 | Lancet 2026, PMID 41865758 |
| CDR-SB change from baseline | CDR-SB score worsened by 2·3 and 2·2 with semaglutide vs 2·3 and 2·1 with placebo in the two trials. | Human RCTn = 3808 | Lancet 2026, PMID 41865758 |
| Cognitive deficit and dementia | Semaglutide was associated with lower risk of cognitive deficit (hazard ratio 0.72 vs sitagliptin and glipizide) and dementia (0.52 vs sitagliptin); observational association only. | Human observational | EClinicalMedicine 2024, PMID 39764175 |
| First-time Alzheimer disease diagnosis | Semaglutide was associated with lower risk of a first Alzheimer diagnosis (hazard ratio 0.33 vs insulin, 0.59 vs other GLP-1 drugs); observational association only. | Human observationaln = 1094761 | Alzheimer's & dementia 2024, PMID 39445596 |
Semaglutide and cognition are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 2 Oct 2026). Grades follow our .
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Dementia, brain fog and what the trials tested
MedlinePlus defines dementia as a loss of mental functions severe enough to affect daily life; brain fog is a search term rather than a diagnosis.[4]
The only randomised test of semaglutide in a memory disease is the pair of phase 3 trials in early symptomatic Alzheimer's disease using oral semaglutide, and their summary is negative.[1]
On the trials' main scale (CDR-SB), scores rose by similar amounts on semaglutide and placebo over two years.[1]
Observational signals, and why they differ from the trial
A health-record cohort of people with type 2 diabetes found lower rates of recorded cognitive deficit and dementia after semaglutide than after some other diabetes drugs, but it cannot show cause and effect.[2]
A far larger cohort found fewer first-time Alzheimer diagnoses with semaglutide, strongest against insulin, but the comparison groups differ in more ways than the drug.[3]
Other peptides people research for cognition
Common questions
Does Semaglutide help with cognition?
The strongest study we summarise for cognition is human rct evidence, across 3 studies with an outcome for cognition. A trial result is not an approval; see the legal status.
Is Semaglutide approved for cognition?
Semaglutide is FDA approved (Ozempic, Wegovy, Rybelsus). Which conditions that approval covers is set by the label; use for anything else is off-label.
Does semaglutide help with brain fog?
None of the studies we cached measured brain fog; the cognition evidence is about dementia and recorded cognitive deficit.[2]
Can semaglutide prevent or slow dementia?
In people who already had early Alzheimer's disease, the phase 3 trials found it did not slow progression; whether it lowers the chance of getting dementia is only suggested by cohort studies.[1]
More on Semaglutide
Sources
- 1Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.Lancet (London, England) · 2026PMID 41865758Accessed 2 Oct 2026
- 212-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study.EClinicalMedicine · 2024PMID 39764175Accessed 2 Oct 2026
- 3Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024PMID 39445596Accessed 2 Oct 2026
- 4medlineplus.gov pagemedlineplus.gov · web pagemedlineplus.gov
Found an error? Report a correction.